

Michael B. Atkins, M.D.

Dr. Atkins is an internationally recognized leader in translational and clinical research. He began his career at Tufts Medical Center before moving to Beth Israel Deaconess Medical Center and being appointed Professor at Harvard Medical School where he served as Deputy Chief of the Division of Hematology/Oncology and leader of the Biologic Therapy and Cutaneous Oncology Programs, as well as Co-PI of the Harvard Skin Cancer SPORE, leader of the Dana Farber Harvard Cancer Center Kidney Cancer Program and Director of the DF/HCC Kidney Cancer SPORE. In 2012, he moved to Georgetown where he is the Deputy Director of the Georgetown Lombardi Comprehensive Cancer Center and William M. Scholl Professor and Vice Chair of the Department of Oncology. He leads the Lombardi Immunotherapy Initiative and institutional Pilot Grants. His current research focuses on immunotherapy for melanoma and RCC and biomarkers for response and toxicity. He has published over 450 original research and review articles and 4 books and has lectured extensively on these topics. He is past president of the Society for Immunotherapy of Cancer and currently co-Chair of the Melanoma Research Foundation Scientific Advisory Council.